CTLA4 and non-small cell lung carcinoma: ICBs have demonstrated significant clinical benefit in NSCLC patients, including antibodies targeting programmed death receptor-1 (PD-1), its ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4).